--- title: "Sino Biopharmaceutical (1177) stock and investor profile" url: "https://aibio.space/companies/sino-biopharmaceutical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Sino Biopharmaceutical Limited (HKEX: 1177), Hong Kong. The directory classifies it as Pharmaceuticals: Major." --- 1177 Sino Biopharmaceutical Limited HKEX · Hong Kong # Sino Biopharmaceutical (1177) news Sino Biopharmaceutical Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1177, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Sino Biopharmaceutical news We have not published a story on Sino Biopharmaceutical yet. When there is news, it will appear here. ## Sino Biopharmaceutical at a glance - **Ticker**: 1177 - **Listing**: HKEX - **Country**: Hong Kong ### Related companies - [Extrawell Pharmaceutical Holdings](https://aibio.space/companies/extrawell-pharmaceutical/) HKEX: 858 - [Regent Pacific Group](https://aibio.space/companies/regent-pacific/) HKEX: 575 - [Pak Fah Yeow International](https://aibio.space/companies/pak-fah-yeow-international/) HKEX: 239 - [China Regenerative Medicine International](https://aibio.space/companies/china-regenerative-medicine-international/) HKEX: 8158 - [Beijing Tong Ren Tang Chinese Medicine Co.](https://aibio.space/companies/beijing-tong-ren-tang-chinese-medicine/) HKEX: 3613 - [Dawnrays Pharmaceutical Holdings](https://aibio.space/companies/dawnrays-pharmaceutical/) HKEX: 2348 - [China Resources Pharmaceutical Group](https://aibio.space/companies/china-resources-pharmaceutical/) HKEX: 3320 - [China Traditional Chinese Medicine Holdings Co.](https://aibio.space/companies/china-traditional-chinese-medicine/) HKEX: 570 ### Also on HKEX - [China Health Group](https://aibio.space/companies/china-health/) 8225 - [JBM (Healthcare)](https://aibio.space/companies/jbm-healthcare/) 2161 - [New Ray Medicine International Holding](https://aibio.space/companies/new-ray-medicine-international/) 6108 - [Guangzhou Innogen Pharmaceutical Group Co](https://aibio.space/companies/guangzhou-innogen-pharmaceutical/) 2591 - [China Traditional Chinese Medicine Holdings Co.](https://aibio.space/companies/china-traditional-chinese-medicine/) 570 - [Sunshine Lake Pharma Co.](https://aibio.space/companies/sunshine-lake-pharma/) 6887 ## Questions about Sino Biopharmaceutical What is the ticker symbol of Sino Biopharmaceutical? Sino Biopharmaceutical Limited trades under the ticker 1177 on HKEX. Where is Sino Biopharmaceutical listed? Sino Biopharmaceutical Limited is listed on HKEX. Our directory also records these other listings: GETTEX:SMZ1; LS:A0CBDJ; OTC:SBHMY; OTC:SBMFF; SET:SINOBIO19. What is the SEC CIK of Sino Biopharmaceutical? The SEC Central Index Key (CIK) for Sino Biopharmaceutical Limited is 1604982. Its filings are on SEC EDGAR. Which country or territory is Sino Biopharmaceutical listed under? Our directory records Sino Biopharmaceutical Limited under Hong Kong. What does Sino Biopharmaceutical do? Our directory classifies Sino Biopharmaceutical Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Sino Biopharmaceutical? The ISIN recorded for Sino Biopharmaceutical Limited is KYG8167W1380. Does aibio.space cover Sino Biopharmaceutical? aibio.space lists Sino Biopharmaceutical Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sino Biopharmaceutical incorporated? SEC records list its state or country of incorporation as E9. Where is Sino Biopharmaceutical headquartered? SEC records list its business address as 60 WALL STREET, NEW YORK, NY, 10005. When does Sino Biopharmaceutical's fiscal year end? Sino Biopharmaceutical Limited's fiscal year ends on December 31, per SEC records. Which companies are similar to Sino Biopharmaceutical? Companies in our directory listed in the same country and business area as Sino Biopharmaceutical: Extrawell Pharmaceutical Holdings, Regent Pacific Group, Pak Fah Yeow International, China Regenerative Medicine International, Beijing Tong Ren Tang Chinese Medicine Co., Dawnrays Pharmaceutical Holdings. ## Investor discussion: Sino Biopharmaceutical Members talk about Sino Biopharmaceutical (1177). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sino Biopharmaceutical, newest first. Each line links the filing it comes from. 1. 2026-04-29 Financings Share or debt issue: GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042901388.pdf) 2. 2026-03-30 Financings Share or debt issue: COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033000668.pdf) 3. 2026-03-26 Listings Share consolidation: CHANGE OF STOCK SHORT NAME IN ENGLISH AND COMPANY WEBSITE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0326/2026032600614.pdf) 4. 2026-01-13 Financings Share or debt issue: SHARE TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0113/2026011300487.pdf) 5. 2025-07-22 Mergers Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FULL ACQUISITION OF LANOVA MEDICINES. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0722/2025072200265.pdf) 6. 2025-07-15 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - FULL ACQUISITION OF LANOVA MEDICINES. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0715/2025071500770.pdf) 7. 2025-04-29 Financings Share or debt issue: GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; ADOPTION OF THE NEW ARTICLES; AND NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042902720.pdf) ## Press releases Headlines of Sino Biopharmaceutical's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT - TQ-A3334 "TLR7 AGONIST" AND TQA3605 "CORE PROTEIN ALLOSTERIC MODULATOR" GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CDE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1027/2026102700048.pdf) 2. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF TQB2102 "HER2 BIPARATOPIC ADC" PRESENTED AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1026/2026102600039.pdf) 3. 2026-10-20 HKEXnews [VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL PARTICIPANTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC2731 INJECTION "TSLP MONOCLONAL ANTIBODY" FOR CHRONIC SINUSITIS WITH NASAL POLYPS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1021/2026102100047.pdf) 4. 2026-10-14 HKEXnews [VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS ON TQ-A3334 "TLR7 AGONIST" AND BEPIROVIRSEN "ASO" TO BE PRESENTED AT 2026 AASLD](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1014/2026101400833.pdf) 5. 2026-10-08 HKEXnews [VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL SUBJECTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR"](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1008/2026100800669.pdf) 6. 2026-09-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC BIOSIMILARS PARTNERSHIP WITH STADA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0928/2026092800686.pdf) 7. 2026-09-24 HKEXnews [NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0924/2026092400840.pdf) 8. 2026-09-24 HKEXnews [NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0924/2026092400822.pdf) 9. 2026-09-15 HKEXnews [VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQH2722 INJECTION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0916/2026091600033.pdf) 10. 2026-09-15 HKEXnews [VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQB2102 INJECTION "HER2 BISPECIFIC ADC"](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0916/2026091600029.pdf) 11. 2026-09-11 HKEXnews [CONNECTED TRANSACTION - ACQUISITION OF 5% EQUITY INTEREST IN CT TIANQING THROUGH THE ACQUISITION OF EQUITY INTERESTS IN THE TARGET COMPANY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0911/2026091100306.pdf) 12. 2026-09-08 HKEXnews [VOLUNTARY ANNOUNCEMENT - TQH5528 "ORAL STAT6 DEGRADER" PRECLINICAL STUDY DATA PRESENTED AT ERS 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0908/2026090800588.pdf) 13. 2026-09-07 HKEXnews [VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL DATA FOR TQC3721 INHALED POWDER FORMULATION, A "PDE3/4 INHIBITOR", PRESENTED AT ERS 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0907/2026090700959.pdf) 14. 2026-09-03 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB6426 "GPC3 ADC" APPROVED BY FDA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0903/2026090302343.pdf) 15. 2026-08-31 HKEXnews [VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR TQB2102 WITH CIPLA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0831/2026083101449.pdf) 16. 2026-08-31 HKEXnews [VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL TRIAL OF KYLO-11 "LPA SIRNA" PRESENTED AT ESC 2026 AND PUBLISHED IN THE LANCET](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0831/2026083100251.pdf) 17. 2026-08-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-364 "NECTIN-4 TME ADC" APPROVED BY NMPA AND FDA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082800467.pdf) 18. 2026-08-21 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF6422 INJECTION "ACTRIIA/B MONOCLONAL ANTIBODY" APPROVED BY THE NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100875.pdf) 19. 2026-08-19 HKEXnews [INTERIM DIVIDEND FOR 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0819/2026081900300.pdf) 20. 2026-08-19 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0819/2026081900298.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:1177 on TradingView](https://www.tradingview.com/symbols/HKEX-1177/). ## SEC filings and registration - **SEC name**: Sino Biopharmaceutical Limited/ADR - **CIK**: 1604982 - **US tickers**: SBMFF (OTC) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Business address**: 60 WALL STREET, NEW YORK, NY, 10005 - **Phone**: 212-250-1905 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001604982), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sino Biopharmaceutical Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1177, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sino Biopharmaceutical Limited - **Ticker**: 1177 - **Listing**: HKEX - **Country or territory**: Hong Kong - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG8167W1380 - **Other listed symbols**: GETTEX:SMZ1; LS:A0CBDJ; OTC:SBHMY; OTC:SBMFF; SET:SINOBIO19 - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-1177/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sino-biopharmaceutical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sino Biopharmaceutical (1177) stock and investor profile", 2026-10-31, https://aibio.space/companies/sino-biopharmaceutical/